D.IMP: 1 |
D.1.2 and D.1.3 | IMP Role | Test |
D.2 | Status of the IMP to be used in the clinical trial |
D.2.1 | IMP to be used in the trial has a marketing authorisation | No |
D.2.5 | The IMP has been designated in this indication as an orphan drug in the Community | No |
D.2.5.1 | Orphan drug designation number | |
D.3 Description of the IMP |
D.3.1 | Product name | Custodiol-N® |
D.3.4 | Pharmaceutical form | Solution for infusion |
D.3.4.1 | Specific paediatric formulation | Information not present in EudraCT |
D.3.7 | Routes of administration for this IMP | Intraarterial use Intracardiac use Intracoronary use
|
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Sodium chloride |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 4,0 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Potassium chloride |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 10,0 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Magnesium chloride hexahydrate |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 8,0 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Calcium chloride dihydrate |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 0,02 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Histidine |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 124,0 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | N-Acetylhistidine |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 57,0 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Sucrose |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 33,0 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | alpha-Ketoglutarate |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 1,81 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Asparaginsäure |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 5,0 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Glycine |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 10,0 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Alanine |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 5,0 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Tryptophan |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 2,0 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Deferoxamine |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 0,0153 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | LK614 (3,4-Dimethoxy-N-methylbenzohydroxamic acid) |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 0,0062 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Arginine |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 3,0 |
D.3.11 The IMP contains an: |
D.3.11.1 | Active substance of chemical origin | Yes |
D.3.11.2 | Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) | No |
| The IMP is a: |
D.3.11.3 | Advanced Therapy IMP (ATIMP) | Information not present in EudraCT |
D.3.11.3.1 | Somatic cell therapy medicinal product | No |
D.3.11.3.2 | Gene therapy medical product | No |
D.3.11.3.3 | Tissue Engineered Product | Information not present in EudraCT |
D.3.11.3.4 | Combination ATIMP (i.e. one involving a medical device) | Information not present in EudraCT |
D.3.11.3.5 | Committee on Advanced therapies (CAT) has issued a classification for this product | Information not present in EudraCT |
D.3.11.4 | Combination product that includes a device, but does not involve an Advanced Therapy | Information not present in EudraCT |
D.3.11.5 | Radiopharmaceutical medicinal product | No |
D.3.11.6 | Immunological medicinal product (such as vaccine, allergen, immune serum) | No |
D.3.11.7 | Plasma derived medicinal product | No |
D.3.11.8 | Extractive medicinal product | No |
D.3.11.9 | Recombinant medicinal product | Information not present in EudraCT |
D.3.11.10 | Medicinal product containing genetically modified organisms | No |
D.3.11.11 | Herbal medicinal product | No |
D.3.11.12 | Homeopathic medicinal product | No |
D.3.11.13 | Another type of medicinal product | No |
D.IMP: 2 |
D.1.2 and D.1.3 | IMP Role | Comparator |
D.2 | Status of the IMP to be used in the clinical trial |
D.2.1 | IMP to be used in the trial has a marketing authorisation | Yes |
D.2.1.1.1 | Trade name | Custodiol® |
D.2.1.1.2 | Name of the Marketing Authorisation holder | Dr. F. Köhler Chemie GmbH |
D.2.1.2 | Country which granted the Marketing Authorisation | Germany |
D.2.5 | The IMP has been designated in this indication as an orphan drug in the Community | No |
D.2.5.1 | Orphan drug designation number | |
D.3 Description of the IMP |
D.3.1 | Product name | Custodiol® |
D.3.4 | Pharmaceutical form | Solution for infusion |
D.3.4.1 | Specific paediatric formulation | Information not present in EudraCT |
D.3.7 | Routes of administration for this IMP | Intraarterial use Intracardiac use Intracoronary use
|
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Sodium chlorid |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 15,0 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Potassium chloride |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 9,0 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Magnesium chloride hexahydrate |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 4,0 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Histidinhydrochloride Monohydrate |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol millimole(s) |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 18,0 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Histidine |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 180,0 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Tryptophan |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 2,0 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Mannitole |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 30,0 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | Calcium chloride dihydrate |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 0,015 |
D.3.8 to D.3.10 IMP Identification Details (Active Substances) |
D.3.8 | INN - Proposed INN | alpha-Ketoglutarate |
D.3.10 | Strength |
D.3.10.1 | Concentration unit | mmol/l millimole(s)/litre |
D.3.10.2 | Concentration type | equal |
D.3.10.3 | Concentration number | 1,0 |
D.3.11 The IMP contains an: |
D.3.11.1 | Active substance of chemical origin | Yes |
D.3.11.2 | Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) | No |
| The IMP is a: |
D.3.11.3 | Advanced Therapy IMP (ATIMP) | Information not present in EudraCT |
D.3.11.3.1 | Somatic cell therapy medicinal product | No |
D.3.11.3.2 | Gene therapy medical product | No |
D.3.11.3.3 | Tissue Engineered Product | Information not present in EudraCT |
D.3.11.3.4 | Combination ATIMP (i.e. one involving a medical device) | Information not present in EudraCT |
D.3.11.3.5 | Committee on Advanced therapies (CAT) has issued a classification for this product | Information not present in EudraCT |
D.3.11.4 | Combination product that includes a device, but does not involve an Advanced Therapy | Information not present in EudraCT |
D.3.11.5 | Radiopharmaceutical medicinal product | No |
D.3.11.6 | Immunological medicinal product (such as vaccine, allergen, immune serum) | No |
D.3.11.7 | Plasma derived medicinal product | No |
D.3.11.8 | Extractive medicinal product | No |
D.3.11.9 | Recombinant medicinal product | Information not present in EudraCT |
D.3.11.10 | Medicinal product containing genetically modified organisms | No |
D.3.11.11 | Herbal medicinal product | No |
D.3.11.12 | Homeopathic medicinal product | No |
D.3.11.13 | Another type of medicinal product | No |